CompletedPhase 2NCT02900976
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Birte Wistinghausen, M.DChildren's Oncology Group
- Intervention
- Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes(biological)
- Enrollment
- 18 target
- Eligibility
- 29 years · All sexes
- Timeline
- 2017 – 2025
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- Phoenix Childrens Hospital, Phoenix, Arizona, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Mattel Children's Hospital UCLA, Los Angeles, California, United States
- Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02900976 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- ACTIVE NOT RECRUITINGNCT06422715PTLD: Multicentric Retrospective StudyFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE1, PHASE2NCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Washington University School of Medicine
- RECRUITINGPHASE2NCT05453396Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesUniversity of Washington
- RECRUITINGPHASE2NCT05786040Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderTimothy Voorhees
See all trials for Post-transplant lymphoproliferative disease →